期刊文献+

系统性红斑狼疮相关骨质疏松 被引量:7

Emphasis on systemic lupus erythematosus and osteoporosis
原文传递
导出
摘要 随着对系统性红斑狼疮诊治认识的发展,骨质疏松作为其长期并发症之一得到更多的关注与研究。系统性红斑狼疮合并骨质疏松的原因包括疾病本身的病程及损害,慢性多器官功能异常,治疗药物因素等多方面,其中除传统研究中证明的因素外,系统活动性炎症,体内激素水平、月经周期,神经精神因素等也参与其发生,最终表现为骨量流失增加,骨组织的细微结构破坏导致承重力下降,甚至骨折,治疗中应予以重视。 As the survival of patients with systemic lupus erythematosus (SLE) has extended obviously osteoporosis as one of its long- term complications gets more attention. The causes of steoporosis in SLE patients include disease duration, systemic inflammation, chronic multiple-organ damage, medications, in addition to the traditional factors, for inatance, hormone levels, menstrual cycle, and neuropsychological factors. Osteoporosis characterized by increased bone loss, subtle structural failure will eventually lead to the decrease of the bearing force of bone tissue and fracture.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第10期810-813,共4页 Chinese Journal of Practical Internal Medicine
关键词 系统性红斑狼疮 骨质疏松 骨密度 危险因素 systemic lupus erythematosus osteoporosis bone mineral density risk factors
  • 相关文献

参考文献19

  • 1Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus [J]. Lupus, 2005, 14(2): 106-112.
  • 2Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus [J]. Arthritis Care & Research, 2012, 64(1): 2-8.
  • 3Chi Chiu Mok, Sik Nin Wong, Kwok Man Ma. Childhood-onset disease carries a higher risk of low bone mineral density in an adult population of systemic lupus erythematosus[J]. Rheumatology, 2012, 51: 468-475.
  • 4Mario Garcia-Carrasco, Claudia Mendoza-Pinto, Ricardo O, et al. Osteoporosis in Patients with systemic lupus erythematosus[J]. IMAJ, 2009, 11 (8): 486-491.
  • 5Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases [J]. Reumatismo, 2014, 66(2):125-35.
  • 6Tang Y1, Xie H, Chen J, et al. Activated NF- κ B in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling[J]. Stem Ceils Dev, 2013, 22(4): 668-678.
  • 7Bultink IE, Harvey NC, Lalmohamed A, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosns versus matched controls: a population-based study in the United Kingdom[J]. Osteoporos Int, 2014, 25(4): 1275-1283.
  • 8Bultink IE. Vis M, van der Horst-Bruinsma IE, et al. Inflammatory rheumatic disorders and bone[J]. Curr Rheumatol Rep, 2012, 14(3): 224-230.
  • 9张学武,刘湘源.再谈糖皮质激素诱导的骨质疏松的诊治[J].中华风湿病学杂志,2013,17(6):361-362. 被引量:6
  • 10李姝玉,胡大伟.系统性红斑狼疮患者骨质疏松的相关因素[J].中国骨质疏松杂志,2007,13(6):447-450. 被引量:5

二级参考文献14

  • 1Mckenzie R, Reynolds JC, CKFallon A, et al. Decreased bonemineral density during low dose glucocorticoid administration in arandomized, placebo controlled trial. J Rheumatol, 2000 , 27:2222-2226.
  • 2Recommendations for the prevention and glucocorticoid-inducedosteoporosis: 2001 update. American College of RheumatologyAd Hoc Committee on glucocorticoid-induced osteoporosis.Arthritis Rheum, 2001,44: 1496-1503.
  • 3Kaji H, Yamauchi M, Chihara K,et al. The threshold of bonemineral density for vertebral fracture in female patients withglucocorticoid-induced osteoporosis. EndocrJ,2006, 53: 27-34.
  • 4Kanis JA, Johansson H, Oden A, et al. A meta-analysis of priorcorticosteroid use and fracture risk. J Bone Miner Res, 2004,19: 893-899.
  • 5Kanis JA, Oden A, Johansson H,et al. FRAX and its applica-tions to clinical practice. Bone, 2009, 44: 734-743.
  • 6Grossman JM, Gordon R, Ranganath VK, et al. American col-lege of rheumatology 2010 recommendations for the preventionand treatment of glucocorticoid-induced osteoporosis. ArthritisCare Res, 2010,62: 1515-1526.
  • 7Bischolf-Ferrari HA, Dawson-Hughes B, Staehelin HB,et al.Fall prevention with supplemental and active forms of vitamin D:a meta analysis of randomised controlled trials. Br Med J, 2009,339: b369.
  • 8Black DM,Cummings SR, Karpf D, et al. Randomized trial ofeffect of alendronate on risk of fracture in women with existingvertebral fractures. Lancet, 1996, 348: 1535-1541.
  • 9Delmas PD, Recker RR, Chesnut CH IQ , et al. Daily and inter-mittent oral ibandronate normalize bone turnover and providesignificant reduction in vertebralfracture risk: results from theBONE study. Osteoporos Int, 2004,15: 792-798.
  • 10McClung MR, Geusens P, Miller PD, et al. Effect of risedronateon the risk of hip fracture in elderly women. N Engl J Med,2001,344: 333-340.

共引文献9

同被引文献68

  • 1张政,林丽贞,陈迪,白发臣,李秋景.福建地区狼疮性肾炎中医证型分布规律回顾性分析[J].福建中医药,2013,44(4):7-8. 被引量:4
  • 2张增利,李冰燕,童建.利用基因敲除小鼠研究维生素D在免疫功能发育中的作用[J].中华微生物学和免疫学杂志,2007,27(3):260-263. 被引量:7
  • 3Zieglar SF, Roan F, Bell BD, et al. The biology of thymic stromal lymphopoietin (TSLP) [J]. Adv Pharmacol, 2013, 66: 129-155.
  • 4Moret FM, Hack CE, van der Wurff-Jacobs KMG, et al. Thymic stromal lymphopoietin ( TSLP ) .. a novel proinflammatory mediator in rheumatoid arthritis that potently activates CDlc (q-) myeloid dendritic cells to attract and stimulate T cells [J]. Arthritis Rheum, 2014, 66 (5): 1176-1184.
  • 5Usategui A, Criado G, Izquierdo E, et al. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis [J]. Ann Rheum Dis, 2013, 72 (12): 2018-2023.
  • 6Hillen MR, Kruize AA, Bikker A, et al. Decreased expression of thymic stroma] lymphopoietin in salivary glands of patients with primary Sj6gren' s syndrome is associated with increased disease activity ['J]. Mod Rheumatol, 2016, 26 (1) .. 105-109.
  • 7Koyama K, Ozawa T, Hatsushika K, et al. A possible role for TSLP in inflammatory arthritis [J]. Biochem Biophys Res Commun, 2007, 357 (1): 99-104.
  • 8Hartgring SA, Willis CR, Dean CE Jr, et al. Critical proinflammatory role of thymie stromal lymphopoietin and its receptor in experimental autoimmune arthritis [J]. Arthritis Rheum, 2011, 63 (7): 1878-1887.
  • 9Ellison CA, Lissitsyn YV, Gheorghiu I. Immunomodulatory effects of palifermin (recombinant human keratinocyte growth factor) in an SLE-like model of chronic graft-versus-host disease [J]. Scand J Immunol, 2012, 75 (1): 69-76.
  • 10Friend SL, Hosier S, Nelson A, et al. A thymic stromal cell line supports in vitro development of surface IgMq- B ceils and produces a novel growth factor affecting B and T lineage ceils [J]. Exp Hematol, 1994, 22 (3): 321-328.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部